Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02419703 · ClinicalTrials.gov registry record

The STAR™ Tumor Ablation Registry

A clinical trial, sponsored by Merit Medical Systems.

Terminated
Registry status
65
Enrollment target

NCT02419703: Clinical Trial study, sponsored by Merit Medical Systems.

NCT02419703 is a clinical trial that was terminated before completion, run by Merit Medical Systems. The registered enrollment target is 65 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02419703 was terminated before completion, sponsored by Merit Medical Systems.

TERMINATED
Registry status
65 participants
Enrollment target

Study Summary

Registry collecting data on use of The STAR™ Tumor Ablation System.

Primary Outcome

measured by Numerical Rating Pain Scale (NRPS, 0-10 scale)

Interventions

  • DEVICE STAR™ Tumor Ablation System

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2015-10
Est. Completion 2017-03-20
Merit Medical Systems

18 total trials

Why NCT02419703 stopped before completion

NCT02419703 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 65 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which STAR™ Tumor Ablation System is the first listed.

NCT02419703 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02419703 about?

NCT02419703 is a clinical study titled "The STAR™ Tumor Ablation Registry". Registry collecting data on use of The STAR™ Tumor Ablation System.

What is the current status of trial NCT02419703?

This trial is currently terminated. The enrollment target is 65 participants. The study started on 2015-10. Estimated completion is 2017-03-20.

What interventions are being tested in trial NCT02419703?

The interventions under investigation include: STAR™ Tumor Ablation System (DEVICE).

Who is sponsoring clinical trial NCT02419703?

This trial is sponsored by Merit Medical Systems, which has 18 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03366116 · 65 participants · Phase 1

    5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

  • NCT03603730 · 65 participants · NA

    Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis

  • NCT03796559 · 65 participants · NA

    Magseed Enabled Long-Term Localization of Axillary Lymph Nodes

  • NCT03993106 · 65 participants · Phase 2

    A Study of sEphB4-HSA in Kaposi Sarcoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02419703, the US trial registry maintained by the National Library of Medicine. NCT02419703 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.